Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality

International Journal of Molecular Sciences
Andreas PircherIsabel Heidegger

Abstract

In recent years, considerable advances concerning therapeutic strategies in patients with metastatic cancer have been achieved. Particularly in renal cell cancer (RCC) and advanced stage non-small cell lung cancer (NSCLC), immune-activating and antiangiogenic (AA) drugs (i.e., checkpoint antibodies and vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFR) targeting compounds, respectively) have been successfully developed. As immune-effector cells have to enter the tumor, it is tempting to speculate that the combination of immunotherapy with AA treatment may induce synergistic effects. In this short review, we explore the theoretical background and the therapeutic potential of this novel treatment option for patients with advanced RCC or NSCLC. We discuss the growing body of evidence that pro-angiogenic factors negatively modulate the T-cell-mediated immune response and examine the preclinical evidence for testing combined immune-activating and AA therapy concepts in clinical practice. Particular attention will also be paid to potential novel treatment-related adverse events induced by combination treatment.

References

Jan 31, 2006·European Urology·Antonio Lopez-BeltranZiya Kirkali
Apr 4, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Anita E M DirkxArjan W Griffioen
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Mar 4, 2008·Cancer Treatment Reviews·Kiran GuptaClaudie Charbonneau
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James H FinkeRonald Bukowski
Mar 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jennifer S KoJames H Finke
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jun 2, 2011·Nature Reviews. Drug Discovery·Peter Carmeliet, Rakesh K Jain
Aug 11, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Judith ManolaUNKNOWN International Kidney Cancer Working Group
Oct 10, 2012·Proceedings of the National Academy of Sciences of the United States of America·Yuhui HuangMark C Poznansky
Aug 3, 2013·The Journal of Clinical Investigation·Jonathan WeltiPeter Carmeliet
Apr 29, 2015·Journal of Cellular Physiology·Dominik WolfAnna Maria Wolf
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Nov 19, 2015·Proceedings of the National Academy of Sciences of the United States of America·Sara M TolaneyRakesh K Jain
Dec 5, 2015·Frontiers in Immunology·Christopher V Carman, Roberta Martinelli
Feb 9, 2016·Lancet·Gordon C JaysonAdrian L Harris
Aug 3, 2016·The Journal of Clinical Investigation·Anne-Theres Henze, Massimiliano Mazzone
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S NovelloUNKNOWN ESMO Guidelines Committee
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Oct 13, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Christian ManegoldEverett Vokes
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 14, 2017·Expert Opinion on Therapeutic Targets·Anna Rita CantelmoPeter Carmeliet
Apr 14, 2017·Science Translational Medicine·Elizabeth AllenGabriele Bergers
Apr 26, 2017·Developmental Cell·Bernard Thienpont, Diether Lambrechts
May 18, 2017·Immunity·Michele De Palma, Rakesh K Jain
Jul 15, 2017·Nature Reviews. Cancer·Michele De PalmaTatiana V Petrova
Jul 22, 2017·Journal of Autoimmunity·Antonio Sica, Marco Massarotti

❮ Previous
Next ❯

Citations

Dec 7, 2018·Japanese Journal of Clinical Oncology·Takeru KashiwadaAkihiko Gemma
Apr 12, 2019·Clinical & Experimental Metastasis·Johannes A Eble, Stephan Niland
Mar 7, 2020·Journal of Clinical Medicine·Paola CiciolaRoberto Bianco
Jul 2, 2019·Frontiers in Oncology·Isabel HeideggerRenate Pichler
Jun 20, 2019·Cancers·Florian CastetJosep Maria Piulats
Jul 4, 2020·Cancer Research·Foteinos-Ioannis D DimitrakopoulosHaralabos P Kalofonos
Mar 20, 2018·Molecular Pharmaceutics·Zheng-Rong Lu, Peter Qiao

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01454102
NCT02443324
NCT02856425
NCT02039674
NCT02366143
NCT01633970
NCT02496208
NCT02133742
NCT02853331
NCT02501096

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Christian ManegoldEverett Vokes
Current Opinion in Oncology
Martin Gutierrez, Giuseppe Giaccone
Current Opinion in Oncology
Tina CasconeFortunato Ciardiello
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Erin M Bertino, Gregory A Otterson
© 2022 Meta ULC. All rights reserved